The medical devices sector is typified by frequent change and innovation, in response to problems and issues faced by the healthcare industry. As a result, the sector has seen the emergence of several start-up medtech companies offering disruptive, cutting-edge solutions. Most of these are private companies, where data such as revenue is frequently not disclosed. National estimates for Cayman Chemical sales in the US from 2016 to 2022, as well as year-on-year growth rates, can be viewed in GlobalData’s micro revenue report. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Cayman Chemical Co, United States Revenue

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

Cayman Chemical Co (Cayman) provides basic research tools for advancing human and animal health. The company offer research products, antibodies, assay kits, biochemicals, proteins, equipment and others. It also provides bioanalysis and assay development services which include sample analysis and screening, lipidomics, activity screening, immunopeptidome profiling, proteomic and PTM analysis, cellular metabolism and bioenergetics analysis. Cayman also offer medicinal chemistry and structure-based drug design; analytical chemistry services such as lipid purification and analysis, drug discovery and custom analytical chemistry services; and chemical synthesis services. The company serves scientists across academic, biotechnology, and pharmaceutical institutions. It has operational presence in the US, Germany and Czech Republic. Cayman is headquartered in Ann Arbor, Michigan, the US. Key subsidiaries of Cayman Chemical include Matreya, Cayman Europe and Cayman Pharma.

The key metrics of Cayman Chemical related to marketed and pipeline products, ongoing clinical trials, active jobs and publications from 2022 are shown below:

As Cayman Chemical is a privately held company, it is not required to disclose its financial information and there is no stock listed on an exchange. GlobalData has access to a proprietary data set containing invoice data from over 2,600 healthcare institutions in the US and is therefore able to use estimations of a company’s revenue and growth to value private companies such as Cayman Chemical.

For a detailed understanding of the performance of Cayman Chemical, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s revenue report leverages GlobalData’s SKU tracker, which contains real-world, purchasing data from the US healthcare institutions.